ArticleScience translational medicine2021
Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
9.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 77 citations in OpenAlex.
- Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound.Scientific reports · 2022Trial
- Article
- The rebound-initiating viral reservoir (RIVR) in SIV/SHIV infection is dominated by plasma virus sequences present at the time of ART initiation.Journal of virology · 2026Article
- CD8ɑ+ cells suppress SIV replication without the development of mutations within MHC class-I-restricted epitopes during post-treatment control.Journal of virology · 2026Article
- Article
- Impact of sex differences in adult and paediatric HIV-1 cure.Current opinion in HIV and AIDS · 2026Review
- Nef and Vpu protect infected cells from ADCP mediated by plasma from people with HIV-1.bioRxiv : the preprint server for biology · 2026Article
- Hydroxylation of the HIV-1 antisense protein promotes immune evasion of HIV-1 via modulation of TBK1.Nature communications · 2026Article
- A Tissue Virus Microenvironment with Activated Stress Responses Underlies Durable SIV Persistence.bioRxiv : the preprint server for biology · 2026Article
- Early immune responses anticipate HIV rebound and precede viral control.bioRxiv : the preprint server for biology · 2026Article
- microRNA-422a promotes HIV replication and innate immune evasion by targeting MECP2.Molecular therapy. Nucleic acids · 2026Article
- Article
- Early Transcriptomic Signatures of Immune Response Modulation Following Antiretroviral Therapy in HIV-Infected Patients.International journal of molecular sciences · 2025Article
- Diagnostic accuracy of the Cepheid MTB host response assay for the detection of pulmonary TB.IJTLD open · 2025Article
- From network biology to immunity: potential longitudinal biomarkers for targeting the network topology of the HIV reservoir.Journal of translational medicine · 2025Review
- SIV proviruses seeded later in infection are harbored in short-lived CD4Cell reports · 2025Article
- Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti-HIV-1 Antibodies.The Journal of infectious diseases · 2025Article
- Phenotyping Viral Reservoirs to Reveal HIV-1 Hiding Places.Current HIV/AIDS reports · 2025Review
- HIV-1 Rebound Virus Consists of a Small Number of Lineages That Entered the Reservoir Close to ART Initiation.bioRxiv : the preprint server for biology · 2025Article
- HIV cure research contributions from Africa in the last three decades.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 14 institutions in 2 countries.
Marcos V P GondimDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0001-5636-9593
Scott Sherrill-MixDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-8955-8072
Frederic Bibollet-RucheDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ronnie M RussellDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0003-1484-4207
Stephanie TrimboliUniversity of Massachusetts Medical School, Worcester, MA 01655, USA.
Andrew G SmithWuXi AppTec Inc., Philadelphia, PA 19112, USA.
Yingying LiDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Weimin LiuDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Alexa N AvittoGene Therapy Program, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0003-1971-4479
Julia C DeVotoDepartment of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Jesse ConnellDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-9393-3074
Angharad E Fenton-MayNuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK.ORCID 0000-0002-6267-1315
Pierre PellegrinoCentre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London WC1E 6JB, UK.
Ian WilliamsCentre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London WC1E 6JB, UK.ORCID 0000-0003-4702-0044
Emmanouil PapasavvasVaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA 19104, USA.
Julio C C LorenziLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-2492-3961
D Brenda SalantesCentury Therapeutics, Philadelphia, PA 19104, USA.ORCID 0000-0001-8214-7804
Felicity MampeDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
M Alexandra MonroyDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Yehuda Z CohenSanofi, Bridgewater, NJ 08807, USA.ORCID 0000-0001-6987-1478
Sonya HeathDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0002-3826-0954
Michael S SaagDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0002-8866-1043
Luis J MontanerVaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0001-5799-6759
Ronald G CollmanDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-0508-3701
Janet M SilicianoDepartment of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0001-6712-3775
Robert F SilicianoDepartment of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0002-1764-1993
Lindsey J PlenderleithInstitute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, UK.
Paul M SharpInstitute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, UK.
Marina CaskeyLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-1727-8693
Michel C NussenzweigLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065, USA.ORCID 0000-0003-0592-8564
George M ShawDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-2338-4532
Persephone BorrowNuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK.ORCID 0000-0002-3877-9780
Katharine J BarDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-9773-0071
Beatrice H HahnDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. bhahn@pennmedicine.upenn.edu.ORCID 0000-0002-9400-9887
University of Pennsylvania · USCentre for Immunity, Infection and Evolution · GBHoward Hughes Medical Institute · USRockefeller University · USThe Wistar Institute · USUniversity College London · GBUniversity of Alabama at Birmingham · USUniversity of Oxford · GBCentury Therapeutics (United States) · USJohns Hopkins University · USSanofi (United States) · USTulane University · USUniversity of Massachusetts Chan Medical School · USWuXi AppTec (United States) · US
Funding
Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4MSupport Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI AHMED, RAFI · 2012 to 2018
$131.5MVirus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7MFirst-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5MCollaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2MTRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6MCharacterizing the viral and host effector mechanisms that govern HIV-1 reboundR01AI162646 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BAR, KATHARINE JUNE, HAHN, BEATRICE H · 2021 to 2025
$4.1M3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoirU01AI129825 · NIAID · ROCKEFELLER UNIVERSITY · PI CASKEY, MARINA · 2017 to 2021
$4.0MTargeting 5' leader-encoded defective ribosomal products for HIV T cell vaccinesR01AI118549 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2016 to 2020
$3.6MReverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine DesignR01AI160607 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2021 to 2024
$3.2MRestriction of HIV-1 transmission by type 1 interferonsR01AI114266 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2014 to 2018
$3.2MMedical Research Council MR/K012037/1NIAID NIH HHS P01 AI131251NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI111789NIAID NIH HHS R01 AI114266NIAID NIH HHS R01 AI118549NIAID NIH HHS R01 AI160607NIAID NIH HHS R01 AI162646NIAID NIH HHS R33 AI133696NIAID NIH HHS T32 AI007632NIAID NIH HHS U01 AI065279NIAID NIH HHS U01 AI129825NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI126619NIAID NIH HHS UM1 AI126620NIAID NIH HHS UM1 AI144371
Abstract
Type 1 interferons (IFN-I) are potent innate antiviral effectors that constrain HIV-1 transmission. However, harnessing these cytokines for HIV-1 cure strategies has been hampered by an incomplete understanding of their antiviral activities at later stages of infection. Here, we characterized the IFN-I sensitivity of 500 clonally derived HIV-1 isolates from the plasma and CD4
Indexed as
HIV-1HIV InfectionsInterferon Type IAntiviral AgentsCD4-Positive T-LymphocytesHumansViral LoadVirus ReplicationAntiviral AgentsInterferon Type I
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.